Department of Gastroenterology, Cangzhou Central Hospital, No. 16 Xinhua West Road, Cangzhou, Hebei 061001, P.R. China.
Tianjin Institute of Acute Abdominal Diseases, Nankai Hospital, Nankai District, Tianjin, 300100, P.R. China.
J Microbiol Biotechnol. 2019 Sep 28;29(9):1478-1487. doi: 10.4014/jmb.1807.06061.
Ulcerative colitis (UC), a chronic inflammatory bowel disease, substantially impacts patients' health-related quality of life. In this study, an effective strategy for discovering high-efficiency probiotics has been developed. First, in order to survive in the conditions of the stomach and intestine, high bile salt-resistant and strong acid-resistant strains were screened out from the fecal flora of healthy adults. Next, the probiotic candidates were rescreened by examining the induction ability of IL-10 (anti-inflammatory factor) production in dextran sodium sulfate (DSS)-induced colitis mice, and () was identified and selected as probiotic P. In the end, fourteen strains isolated from stools of healthy males were examined for their antimicrobial activity. B10 (73.75% inhibition rate) was selected as probiotic B. Moreover, the colonic IL-6 and TNF-α expression of the DSSinduced colitis mice treated with 07 (L07) - B10 combination (PB) significantly decreased and the IL-10 expression was up-regulated by PB compared to the DSS group. Furthermore, and decreased and increased in the DSS group mice, significantly. More interestingly, the intestinal flora biodiversity of DSS colitis mice was increased by PB. Of those, the level of increased significantly. The / (B/F) ratio increased, and the concentration of homocysteine and LPS in plasma was down-regulated by PB in the DSS-induced colitis mice. Upon administration of PB, the intestinal permeability of the the DSS-induced colitis mice was decreased by approximately 2.01-fold. This method is expected to be used in high-throughput screening of the probiotics against colitis. In addition, the 07 - B10 combination holds potential in UC remission by immunomodulatory and gut microbiota modulation.
溃疡性结肠炎（UC）是一种慢性炎症性肠病，极大地影响了患者的健康相关生活质量。在这项研究中，开发了一种发现高效益生菌的有效策略。首先，为了在胃和肠道的条件下生存，从健康成年人的粪便菌群中筛选出高胆汁盐抗性和强酸抗性菌株。接下来，通过检查葡聚糖硫酸钠（DSS）诱导的结肠炎小鼠中 IL-10（抗炎因子）产生的诱导能力，对益生菌候选物进行再筛选，鉴定并选择 作为益生菌 P。最后，检查了从健康男性粪便中分离出的十四株 菌株的抗菌活性。 B10（抑制率 73.75%）被选为益生菌 B。此外，与 DSS 组相比，用 07 （L07）-B10 组合（PB）治疗的 DSS 诱导结肠炎小鼠的结肠 IL-6 和 TNF-α表达显著降低，IL-10 表达上调。此外，DSS 组小鼠的 和 降低， 增加。更有趣的是，PB 增加了 DSS 结肠炎小鼠的肠道菌群多样性。其中， 水平显著增加。/（B/F）比值增加，血浆中同型半胱氨酸和 LPS 浓度下调。PB 治疗可使 DSS 诱导结肠炎小鼠的肠道通透性降低约 2.01 倍。该方法有望用于高通量筛选抗结肠炎益生菌。此外，07-B10 联合用药具有通过免疫调节和肠道菌群调节缓解 UC 的潜力。
